Genmab initiated with a Market Perform at William Blair

William Blair analyst Matt Phipps initiated coverage of Genmab with a Market Perform rating without a price target. Although launch of the company’s partnered programs have significant longer-term potential, initial commercial indications are limited and additional time will be needed for its "intriguing pipeline programs to take shape," Phipps tells investors in a research note. The analyst is also cautions on Genmab’s near-term readouts, such as GEN3014.